Evidence map›Paper›PMID 39402973›Full record

ArticleMolecular pharmaceutics2024

Immuno-PET Imaging of EGFR with

Nasim Sarrami, Melinda Wuest, Igor Moura de Paiva, Samantha Leier, Afsaneh Lavasanifar, Frank Wuest

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nasim SarramiFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H1, Canada.
Melinda WuestDepartment of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2, Canada.
Igor Moura de PaivaFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H1, Canada.ORCID 0000-0002-2077-0016
Samantha LeierDepartment of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2, Canada.
Afsaneh LavasanifarFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H1, Canada.ORCID 0000-0001-5108-7124
Frank WuestFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H1, Canada.ORCID 0000-0002-6705-6450

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungCopper RadioisotopesErbB ReceptorsHeterocyclic Compounds, 1-RingLung NeoplasmsPanitumumabPositron-Emission TomographyXenograft Model Antitumor AssaysAnimalsCell Line, TumorFemaleHeterocyclic CompoundsHumansMiceRadiopharmaceuticalsTissue Distribution1,4,7-triazacyclononane-N,N',N''-triacetic acidCopper-64Copper RadioisotopesEGFR protein, humanErbB ReceptorsHeterocyclic CompoundsHeterocyclic Compounds, 1-RingPanitumumabRadiopharmaceuticals64CuEGFRimmuno-PETnonsmall cell lung cancer (NSCLC)panitumumab

Identifiers

PMID39402973
PMCPMC11539060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.